Posted by admin on Oct 1, 2011 in |
Aim: Primary urinary bladder adenocarcinoma is a rare entity. This is a clinical case presentation with review of the literature on this topic. Primary adenocarcinoma of the urinary bladder has shown a poor response to radiation or chemotherapy individually. Therefore, combination chemotherapy with radical EBRT is the effective therapeutic approach for inoperable cases. Method: A 58 year old male patient referred to the department of Radiotherapy, Regional Cancer Centre, Pt. BDS PGIMS ROHTAK with complaints of gross painless hematuria, dysuria, burning micturation for 5 years. Diagnostic work-up included renal and bladder ultrasound, cystoscopy and CT scan of abdomen and pelvis. CT scan showed mass lesion in urinary bladder infiltrating anterior abdominal wall (primary bladder adeno- carcinoma T4bN0M0). Trans-urethral resection followed by tissue diagnosis revealed an invasive adenocarcinoma. Metastatic disease was ruled out. Patient responded completely to systemic combination chemotherapy including GEMCITABINE and CARBOPLATIN six courses followed by radical external radiotherapy. At 24 months of follow-up, the patient did not present disease progression or systemic complications, after that he developed a nodular lump in neck. FNAC of node showed...
Read More
Posted by admin on Oct 1, 2011 in |
The present study was undertaken to determine the anti-ulcer potential of Calamintha officinalis Moench, a standardized oil of Calamintha officinalis Moench, commonly known as Calamint. Effect of various doses (0.4ml/kg and 0.8ml/kg,) of Calamintha officinalis Moench. oil was studied on gastric ulcers in pylorus ligation, Diclofenac sodium induced gastric mucosal injury in rats. Anti-ulcer activity was evaluated by measuring the ulcer index, gastric content, total acidity, and pH of gastric fluid. Calamintha officinalis Moench, dose dependently decreased gastric content, total acidity, ulcer index and increased pH of gastric fluid in pylorus ligation ulcer model. In Diclofenac sodium induced ulcer models, all the doses of Calamintha officinalis Moench. oil decreased the ulcer index and increased the pH gastric fluid. These results supported the ethnomedical uses of oil of Calamintha officinalis Moench. in the treatment of gastric...
Read More
Posted by admin on Oct 1, 2011 in |
To determine the anticonvulsant activity of the leaf extract of Erythrina Indica in mice and rats, and in order to verify the traditional use of the plant in the treatment of epilepsy. The pentyleneterazole (PTZ) and the maximal electroshock seizure (MES) models were used for assessing the anticonvulsant effects of the chloroform leaf extract in mice and rats. The chloroform extract (500 mg/kg p.o) of that produced significant protection (71.4%) against PTZ-induced convulsion and onset of seizures compared with the control group in mice. At 500 mg/kg p.o., the extract also produced sig-nificant protection (71.4%) against MES-induced convulsions in mice. The results obtained from this study indicate that the chloroform leaf extract of Erythrina Indica may be beneficial in both absence and tonic clonic...
Read More
Posted by admin on Oct 1, 2011 in |
Zymodyne Syrup is poly herbal formulation made by Ayrulab Herbals Pvt. Ltd., as an appetite enhancer. This formulation contains various 17 plant extract from these 6 plants namely Cyperus rotundus, Bacopa monnieri, Glycyrrhiza glabra, Phyllanthus amarus, Asparagus racemosus, and Tribulus terrestris contains Quercetin flavonoid as a chemical constitute and it can be determined by HPTLC method. The concentration of Quercetin in formulation was 0.1100 mcg/ml and in individual extracts were 0.870, 0.783, 0.782, 0.855, 0.875, 0.957 mcg/ml respectively. This study may provide useful information in searching the role of Quercetin to enhance appetite...
Read More
Posted by admin on Oct 1, 2011 in |
The study was designed to determine the relative bioavailability of two sustained release Fixed dose combination (FDC) products of two manufacturers containing Lornoxicam [CAS No. 70374-39-9] 8mg and Thiocolchicoside [CAS No. 602-41-5] 8mg in 24 healthy male volunteers. The pharmacokinetics of Lornoxicam and Thiocolchicoside individually after oral administration of tablet formulation has been extensively evaluated in adult volunteers. However, no published data are available regarding the combined pharmacokinetics and bioavailability of this particular fixed dose combination. The clinical study was randomized, balanced, open-label, 2-period cross-over study. Each subject was randomized at the beginning of the study to receive either a single dose of test fixed dose combination or reference fixed dose combination during Period I. Following a 7-day wash out period, all subjects received the alternate formulation during Period II. No statistically significant differences were obtained between the two products with respect to the mean concentration-time profiles or in the pharmacokinetic parameters, including area under the serum concentration-time curve from the present study. The relative extent of absorption as...
Read More
